Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
29
06
2022
pubmed:
11
8
2022
medline:
1
11
2022
entrez:
10
8
2022
Statut:
ppublish
Résumé
The pathophysiology of irritable bowel syndrome (IBS) is multifactorial and probably involves genetic predisposition and the effect of environmental factors. Unlike other gastrointestinal diseases with a heritable component, genetic research in IBS has been scarce and mostly characterized by small underpowered studies, leading to inconclusive results. The availability of genomic and health-related data from large international cohorts and population-based biobanks offers unprecedented opportunities for long-awaited, well-powered genetic studies in IBS. This Review focuses on the latest advances that provide compelling evidence for the importance of genes involved in the digestion of carbohydrates, ion channel function, neurotransmitters and their receptors, neuronal pathways and the control of gut motility. These discoveries have generated novel information that might be further refined for the identification of predisposed individuals and selection of management strategies for patients. This Review presents a conceptual framework, the advantages and potential limitations of modern genetic research in IBS, and a summary of available evidence.
Identifiants
pubmed: 35948782
doi: 10.1038/s41575-022-00662-2
pii: 10.1038/s41575-022-00662-2
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-702Informations de copyright
© 2022. Springer Nature Limited.
Références
Drossman, D. A. & Tack, J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. Gastroenterology 162, 675–679 (2022).
pubmed: 34808139
doi: 10.1053/j.gastro.2021.11.019
Ford, A. C., Sperber, A. D., Corsetti, M. & Camilleri, M. Irritable bowel syndrome. Lancet 396, 1675–1688 (2020).
pubmed: 33049223
doi: 10.1016/S0140-6736(20)31548-8
Drossman, D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 150, 1262–1279 (2016).
doi: 10.1053/j.gastro.2016.02.032
Drossman, D. A. & Hasler, W. L. Rome IV–functional GI disorders: disorders of gut-brain interaction. Gastroenterology 150, 1257–1261 (2016).
pubmed: 27147121
doi: 10.1053/j.gastro.2016.03.035
Lewis, S. J. & Heaton, K. W. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 32, 920–924 (1997).
pubmed: 9299672
doi: 10.3109/00365529709011203
Buono, J. L., Carson, R. T. & Flores, N. M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes 15, 35 (2017).
pubmed: 28196491
pmcid: 5310011
doi: 10.1186/s12955-017-0611-2
Frändemark, Å., Törnblom, H., Jakobsson, S. & Simrén, M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am. J. Gastroenterol. 113, 1540–1549 (2018).
pubmed: 30254230
doi: 10.1038/s41395-018-0262-x
Camilleri, M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA 325, 865–877 (2021).
pubmed: 33651094
doi: 10.1001/jama.2020.22532
Drossman, D. A. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am. J. Med. 107, 41–50 (1999).
doi: 10.1016/S0002-9343(99)00081-9
Palsson, O. S. & Drossman, D. A. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North. Am. 34, 281–303 (2005).
pubmed: 15862936
doi: 10.1016/j.gtc.2005.02.004
Camilleri, M. Peripheral mechanisms in irritable bowel syndrome. N. Engl. J. Med. 367, 1626–1635 (2012).
pubmed: 23094724
doi: 10.1056/NEJMra1207068
Ohman, L. & Simrén, M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 7, 163–173 (2010).
pubmed: 20101257
doi: 10.1038/nrgastro.2010.4
Bennet, S. M. P., Ohman, L. & Simren, M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 9, 318–331 (2015).
pubmed: 25918261
pmcid: 4413965
doi: 10.5009/gnl14344
Moayyedi, P., Simrén, M. & Bercik, P. Evidence-based and mechanistic insights into exclusion diets for IBS. Nat. Rev. Gastroenterol. Hepatol. 17, 406–413 (2020).
pubmed: 32123377
doi: 10.1038/s41575-020-0270-3
Lackner, J. M. et al. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 11, 1147–1157 (2013).
pubmed: 23524278
pmcid: 3779619
doi: 10.1016/j.cgh.2013.03.011
D’Amato, M. Genes and functional GI disorders: from casual to causal relationship. Neurogastroenterol. Motil. 25, 638–649 (2013).
pubmed: 23826979
doi: 10.1111/nmo.12173
Waehrens, R., Ohlsson, H., Sundquist, J., Sundquist, K. & Zöller, B. Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden. Gut 64, 215–221 (2015).
pubmed: 24694578
doi: 10.1136/gutjnl-2013-305705
Camilleri, M. Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig. Dis. Sci. 54, 2318–2324 (2009).
pubmed: 19655247
pmcid: 2903621
doi: 10.1007/s10620-009-0903-4
Heitkemper, M. M., Kohen, R., Jun, S.-E. & Jarrett, M. E. Genetics and gastrointestinal symptoms. Annu. Rev. Nurs. Res. 29, 261–280 (2011).
pubmed: 22891508
doi: 10.1891/0739-6686.29.261
Saito, Y. A. The role of genetics in IBS. Gastroenterol. Clin. North. Am. 40, 45–67 (2011).
pubmed: 21333900
pmcid: 3056499
doi: 10.1016/j.gtc.2010.12.011
Mawe, G. M. & Hoffman, J. M. Serotonin signalling in the gut–functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 10, 473–486 (2013).
pubmed: 23797870
pmcid: 4048923
doi: 10.1038/nrgastro.2013.105
Bellono, N. W. et al. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell 170, 185–198 (2017).
pubmed: 28648659
pmcid: 5839326
doi: 10.1016/j.cell.2017.05.034
Grudell, A. B. M. et al. An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions. Neurogastroenterol. Motil. 20, 213–219 (2008).
pubmed: 17971028
doi: 10.1111/j.1365-2982.2007.01026.x
Camilleri, M. et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132, 17–25 (2007).
pubmed: 17241856
doi: 10.1053/j.gastro.2006.11.020
Kim, H. J. et al. Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 53, 829–837 (2004).
pubmed: 15138209
pmcid: 1774073
doi: 10.1136/gut.2003.030882
Camilleri, M. et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123, 425–432 (2002).
pubmed: 12145795
doi: 10.1053/gast.2002.34780
Mohr, S. et al. The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. J. Cell. Mol. Med. 25, 8047–8061 (2021).
pubmed: 34165249
pmcid: 8358858
doi: 10.1111/jcmm.16736
Gunn, D. et al. Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron. Aliment. Pharmacol. Ther. 50, 538–546 (2019).
pubmed: 31342534
pmcid: 6772086
doi: 10.1111/apt.15420
Wohlfarth, C. et al. miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Sci. Rep. 7, 14680 (2017).
pubmed: 29089619
pmcid: 5665867
doi: 10.1038/s41598-017-13982-0
Kilpatrick, L. et al. The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 140, 1943–1951 (2011).
pubmed: 21420406
doi: 10.1053/j.gastro.2011.03.011
Niesler, B. et al. 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. Eur. J. Gastroenterol. Hepatol. 22, 856–861 (2010).
pubmed: 19561511
doi: 10.1097/MEG.0b013e32832e9d6b
Kapeller, J. et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum. Mol. Genet. 17, 2967–2977 (2008).
pubmed: 18614545
doi: 10.1093/hmg/ddn195
Li, Y. et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig. Dis. Sci. 52, 2942–2949 (2007).
pubmed: 17394071
doi: 10.1007/s10620-006-9679-y
Boesmans, W., Owsianik, G., Tack, J., Voets, T. & Vanden Berghe, P. TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br. J. Pharmacol. 162, 18–37 (2011).
pubmed: 20804496
pmcid: 3012403
doi: 10.1111/j.1476-5381.2010.01009.x
Fuentes, I. M. & Christianson, J. A. Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol. Motil. 28, 1613–1618 (2016).
pubmed: 27781369
pmcid: 5123675
doi: 10.1111/nmo.12979
Locke, G. R., Ackerman, M. J., Zinsmeister, A. R., Thapa, P. & Farrugia, G. Gastrointestinal symptoms in families of patients with an SCN5A-encoded cardiac channelopathy: evidence of an intestinal channelopathy. Am. J. Gastroenterol. 101, 1299–1304 (2006).
pubmed: 16771953
doi: 10.1111/j.1572-0241.2006.00507.x
Beyder, A. et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology 146, 1659–1668 (2014).
pubmed: 24613995
doi: 10.1053/j.gastro.2014.02.054
Strege, P. R. et al. Irritable bowel syndrome patients have SCN5A channelopathies that lead to decreased NaV1.5 current and mechanosensitivity. Am. J. Physiol. Gastrointest. Liver Physiol. 314, G494–G503 (2018).
pubmed: 29167113
doi: 10.1152/ajpgi.00016.2017
Sanders, K. M., Ward, S. M. & Koh, S. D. Interstitial cells: regulators of smooth muscle function. Physiol. Rev. 94, 859–907 (2014).
pubmed: 24987007
pmcid: 4152167
doi: 10.1152/physrev.00037.2013
Henström, M. et al. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M. Gut 66, 1725–1727 (2017).
pubmed: 27974553
doi: 10.1136/gutjnl-2016-313346
Khanna, R., MacDonald, J. K. & Levesque, B. G. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J. Clin. Gastroenterol. 48, 505–512 (2014).
pubmed: 24100754
doi: 10.1097/MCG.0b013e3182a88357
Gericke, B., Amiri, M. & Naim, H. Y. The multiple roles of sucrase-isomaltase in the intestinal physiology. Mol. Cell. Pediatr. 3, 2 (2016).
pubmed: 26812950
pmcid: 4728165
doi: 10.1186/s40348-016-0033-y
Gericke, B., Amiri, M., Scott, C. R. & Naim, H. Y. Molecular pathogenicity of novel sucrase-isomaltase mutations found in congenital sucrase-isomaltase deficiency patients. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 817–826 (2017).
pubmed: 28062276
doi: 10.1016/j.bbadis.2016.12.017
Alfalah, M., Keiser, M., Leeb, T., Zimmer, K.-P. & Naim, H. Y. Compound heterozygous mutations affect protein folding and function in patients with congenital sucrase-isomaltase deficiency. Gastroenterology 136, 883–892 (2009).
pubmed: 19121318
doi: 10.1053/j.gastro.2008.11.038
Foley, A. et al. Adult sucrase-isomaltase deficiency masquerading as IBS. Gut 71, 1237–1238 (2021).
pubmed: 34615726
doi: 10.1136/gutjnl-2021-326153
Muldoon, C., Maguire, P. & Gleeson, F. Onset of sucrase-isomaltase deficiency in late adulthood. Am. J. Gastroenterol. 94, 2298–2299 (1999).
pubmed: 10445568
doi: 10.1111/j.1572-0241.1999.01320.x
Ringrose, R. E., Preiser, H. & Welsh, J. D. Sucrase-isomaltase (palatinase) deficiency diagnosed during adulthood. Dig. Dis. Sci. 25, 384–387 (1980).
pubmed: 7371476
doi: 10.1007/BF01308064
Henström, M. et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut 67, 263–270 (2018).
pubmed: 27872184
doi: 10.1136/gutjnl-2016-312456
Thingholm, L. et al. Sucrase-isomaltase 15Phe IBS risk variant in relation to dietary carbohydrates and faecal microbiota composition. Gut 68, 177–178 (2019).
pubmed: 29331942
doi: 10.1136/gutjnl-2017-315841
Garcia-Etxebarria, K. et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. Clin. Gastroenterol. Hepatol. 16, 1673–1676 (2018).
pubmed: 29408290
pmcid: 6103908
doi: 10.1016/j.cgh.2018.01.047
Chumpitazi, B. P. et al. Hypomorphic SI genetic variants are associated with childhood chronic loose stools. PLoS ONE 15, e0231891 (2020).
pubmed: 32433684
pmcid: 7239456
doi: 10.1371/journal.pone.0231891
Zheng, T. et al. Rare hypomorphic sucrase isomaltase variants in relation to irritable bowel syndrome risk in UK biobank. Gastroenterology 161, 1712–1714 (2021).
pubmed: 34186061
doi: 10.1053/j.gastro.2021.06.063
Zheng, T. et al. Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants. Gut 69, 397–398 (2020).
pubmed: 30658996
doi: 10.1136/gutjnl-2018-318036
Nilholm, C., Roth, B. & Ohlsson, B. A dietary intervention with reduction of starch and sucrose leads to reduced gastrointestinal and extra-intestinal symptoms in IBS patients. Nutrients 11, E1662 (2019).
pubmed: 31330810
doi: 10.3390/nu11071662
Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385–389 (2005).
pubmed: 15761122
pmcid: 1512523
doi: 10.1126/science.1109557
Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
pubmed: 23128233
pmcid: 3491803
doi: 10.1038/nature11582
Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979–986 (2015).
pubmed: 26192919
pmcid: 4881818
doi: 10.1038/ng.3359
de Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017).
pubmed: 28067908
pmcid: 5289481
doi: 10.1038/ng.3760
Dubois, P. C. A. et al. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42, 295–302 (2010).
pubmed: 20190752
pmcid: 2847618
doi: 10.1038/ng.543
Trynka, G. et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat. Genet. 43, 1193–1201 (2011).
pubmed: 22057235
pmcid: 3242065
doi: 10.1038/ng.998
Coleman, C. et al. Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. Eur. J. Hum. Genet. 24, 291–297 (2016).
pubmed: 25920553
doi: 10.1038/ejhg.2015.87
Smyth, D. J. et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 359, 2767–2777 (2008).
pubmed: 19073967
pmcid: 2840835
doi: 10.1056/NEJMoa0807917
Jefremow, A. & Neurath, M. F. All are equal, some are more equal: targeting IL 12 and 23 in IBD - a clinical perspective. Immunotargets Ther. 9, 289–297 (2020).
pubmed: 33274187
pmcid: 7705252
doi: 10.2147/ITT.S282466
Seyed Tabib, N. S. et al. Big data in IBD: big progress for clinical practice. Gut 69, 1520–1532 (2020).
pubmed: 32111636
doi: 10.1136/gutjnl-2019-320065
Gettler, K. et al. Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort. Gastroenterology 160, 1546–1557 (2021).
pubmed: 33359885
doi: 10.1053/j.gastro.2020.12.034
Uffelmann, E. et al. Genome-wide association studies. Nat. Rev. Methods Prim. 1, 59 (2021).
doi: 10.1038/s43586-021-00056-9
Wijmenga, C. & Zhernakova, A. The importance of cohort studies in the post-GWAS era. Nat. Genet. 50, 322–328 (2018).
pubmed: 29511284
doi: 10.1038/s41588-018-0066-3
Bycroft, C. et al. The UK biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
pubmed: 30305743
pmcid: 6786975
doi: 10.1038/s41586-018-0579-z
Eijsbouts, C. et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat. Genet. 53, 1543–1552 (2021).
pubmed: 34741163
pmcid: 8571093
doi: 10.1038/s41588-021-00950-8
Ek, W. E. et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut 64, 1774–1782 (2015).
pubmed: 25248455
doi: 10.1136/gutjnl-2014-307997
Holliday, E. G. et al. Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am. J. Gastroenterol. 109, 770–772 (2014).
pubmed: 24797007
doi: 10.1038/ajg.2014.56
Bonfiglio, F. et al. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterol. Motil. 30, e13358 (2018).
pubmed: 29673008
doi: 10.1111/nmo.13358
Bonfiglio, F. et al. Female-specific association between variants on chromosome 9 and self-reported diagnosis of irritable bowel syndrome. Gastroenterology 155, 168–179 (2018).
pubmed: 29626450
doi: 10.1053/j.gastro.2018.03.064
Day, F. R. et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat. Genet. 49, 834–841 (2017).
pubmed: 28436984
pmcid: 5841952
doi: 10.1038/ng.3841
Elks, C. E. et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat. Genet. 42, 1077–1085 (2010).
pubmed: 21102462
pmcid: 3140055
doi: 10.1038/ng.714
Heitkemper, M., Jarrett, M., Bond, E. F. & Chang, L. Impact of sex and gender on irritable bowel syndrome. Biol. Res. Nurs. 5, 56–65 (2003).
pubmed: 12886671
doi: 10.1177/1099800403005001006
Kim, Y. S. & Kim, N. Sex-gender differences in irritable bowel syndrome. J. Neurogastroenterol. Motil. 24, 544–558 (2018).
pubmed: 30347934
pmcid: 6175559
doi: 10.5056/jnm18082
Whitehead, W. E. et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 98, 1485–1489 (1990).
pubmed: 2338190
doi: 10.1016/0016-5085(90)91079-L
Norcliffe-Kaufmann, L., Slaugenhaupt, S. A. & Kaufmann, H. Familial dysautonomia: history, genotype, phenotype and translational research. Prog. Neurobiol. 152, 131–148 (2017).
pubmed: 27317387
doi: 10.1016/j.pneurobio.2016.06.003
Camilleri, M. Gastrointestinal motility disorders in neurologic disease. J. Clin. Invest. 131, 143771 (2021).
pubmed: 33586685
doi: 10.1172/JCI143771
Tillisch, K. et al. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 54, 1396–1401 (2005).
pubmed: 15923667
pmcid: 1774694
doi: 10.1136/gut.2004.058685
Viramontes, B. E. et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 96, 2671–2676 (2001).
pubmed: 11569693
doi: 10.1111/j.1572-0241.2001.04138.x
Hogan, A. M., Collins, D., Baird, A. W. & Winter, D. C. Estrogen and its role in gastrointestinal health and disease. Int. J. Colorectal Dis. 24, 1367–1375 (2009).
pubmed: 19655153
doi: 10.1007/s00384-009-0785-0
Taché, Y. & Bonaz, B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest. 117, 33–40 (2007).
pubmed: 17200704
pmcid: 1716215
doi: 10.1172/JCI30085
Bernstein, M. T. et al. Gastrointestinal symptoms before and during menses in healthy women. BMC Women’s Health 14, 14 (2014).
pubmed: 24450290
pmcid: 3901893
doi: 10.1186/1472-6874-14-14
Meleine, M. & Matricon, J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J. Gastroenterol. 20, 6725–6743 (2014).
pubmed: 24944465
pmcid: 4051914
doi: 10.3748/wjg.v20.i22.6725
Houghton, L. A., Lea, R., Jackson, N. & Whorwell, P. J. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 50, 471–474 (2002).
pubmed: 11889064
pmcid: 1773170
doi: 10.1136/gut.50.4.471
Wu, Y. et al. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat. Commun. 12, 1146 (2021).
pubmed: 33608531
pmcid: 7895976
doi: 10.1038/s41467-021-21280-7
Boutwell, B. et al. Replication and characterization of CADM2 and MSRA genes on human behavior. Heliyon 3, e00349 (2017).
pubmed: 28795158
pmcid: 5537199
doi: 10.1016/j.heliyon.2017.e00349
Pasman, J. A. et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat. Neurosci. 21, 1161–1170 (2018).
pubmed: 30150663
pmcid: 6386176
doi: 10.1038/s41593-018-0206-1
Frei, J. A., Andermatt, I., Gesemann, M. & Stoeckli, E. T. The SynCAM synaptic cell adhesion molecules are involved in sensory axon pathfinding by regulating axon-axon contacts. J. Cell. Sci. 127, 5288–5302 (2014).
pubmed: 25335893
Ibrahim-Verbaas, C. A. et al. GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Mol. Psychiatry 21, 189–197 (2016).
pubmed: 25869804
doi: 10.1038/mp.2015.37
Petrovska, J. et al. The NCAM1 gene set is linked to depressive symptoms and their brain structural correlates in healthy individuals. J. Psychiatr. Res. 91, 116–123 (2017).
pubmed: 28334615
doi: 10.1016/j.jpsychires.2017.03.007
Schmid, R. S. & Maness, P. F. L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth. Curr. Opin. Neurobiol. 18, 245–250 (2008).
pubmed: 18760361
pmcid: 2633433
doi: 10.1016/j.conb.2008.07.015
Pappa, S. et al. PHF2 histone demethylase prevents DNA damage and genome instability by controlling cell cycle progression of neural progenitors. Proc. Natl Acad. Sci. USA 116, 19464–19473 (2019).
pubmed: 31488723
pmcid: 6765295
doi: 10.1073/pnas.1903188116
Shi, L. Dock protein family in brain development and neurological disease. Commun. Integr. Biol. 6, e26839 (2013).
pubmed: 24563715
pmcid: 3922786
doi: 10.4161/cib.26839
Detera-Wadleigh, S. D. et al. Sequence variation in DOCK9 and heterogeneity in bipolar disorder. Psychiatr. Genet. 17, 274–286 (2007).
pubmed: 17728666
doi: 10.1097/YPG.0b013e328133f352
Kuramoto, K., Negishi, M. & Katoh, H. Regulation of dendrite growth by the Cdc42 activator Zizimin1/Dock9 in hippocampal neurons. J. Neurosci. Res. 87, 1794–1805 (2009).
pubmed: 19156867
doi: 10.1002/jnr.21997
Nagel, M., Watanabe, K., Stringer, S., Posthuma, D. & van der Sluis, S. Item-level analyses reveal genetic heterogeneity in neuroticism. Nat. Commun. 9, 905 (2018).
pubmed: 29500382
pmcid: 5834468
doi: 10.1038/s41467-018-03242-8
Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221 (2014).
pubmed: 25363768
pmcid: 4313871
doi: 10.1038/nature13908
Whitehead, W. E., Palsson, O. & Jones, K. R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122, 1140–1156 (2002).
pubmed: 11910364
doi: 10.1053/gast.2002.32392
Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160, 636–645 (2003).
pubmed: 12668349
doi: 10.1176/appi.ajp.160.4.636
Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. Am. J. Hum. Genet. 90, 7–24 (2012).
pubmed: 22243964
pmcid: 3257326
doi: 10.1016/j.ajhg.2011.11.029
Camilleri, M. & Katzka, D. A. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1075–G1084 (2012).
pubmed: 22403795
pmcid: 3362100
doi: 10.1152/ajpgi.00537.2011
Camilleri, M. et al. Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders. Gastroenterology 138, 98–107.e4 (2010).
pubmed: 19732772
doi: 10.1053/j.gastro.2009.08.051
Wong, B. S. et al. A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 140, 1934–1942 (2011).
pubmed: 21396369
doi: 10.1053/j.gastro.2011.02.063
D’Amato, M. et al. Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology 133, 808–817 (2007).
pubmed: 17854592
doi: 10.1053/j.gastro.2007.06.012
Camilleri, M. & Nurko, S. Bile acid diarrhea in adults and adolescents. Neurogastroenterol. Motil. 34, e14287 (2021).
pubmed: 34751982
Henström, M. et al. NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-based study. Neurogastroenterol. Motil. 26, 1417–1425 (2014).
pubmed: 25091462
doi: 10.1111/nmo.12401
Degen, L. P. & Phillips, S. F. How well does stool form reflect colonic transit? Gut 39, 109–113 (1996).
pubmed: 8881820
pmcid: 1383242
doi: 10.1136/gut.39.1.109
Zinsmeister, A. R., Burton, D. & Camilleri, M. Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations. Dig. Dis. Sci. 58, 509–518 (2013).
pubmed: 22918691
Jankipersadsing, S. A. et al. A GWAS meta-analysis suggests roles for xenobiotic metabolism and ion channel activity in the biology of stool frequency. Gut 66, 756–758 (2017).
pubmed: 27473416
doi: 10.1136/gutjnl-2016-312398
Bonfiglio, F. et al. GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genom. https://doi.org/10.1016/j.xgen.2021.100069 (2021).
doi: 10.1016/j.xgen.2021.100069
pubmed: 34957435
pmcid: 8654685
Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730.e22 (2019).
pubmed: 31348891
pmcid: 6662628
doi: 10.1016/j.cell.2019.06.029
Drokhlyansky, E. et al. The human and mouse enteric nervous system at single-cell resolution. Cell 182, 1606–1622.e23 (2020).
pubmed: 32888429
pmcid: 8358727
doi: 10.1016/j.cell.2020.08.003
Browning, K. N. & Travagli, R. A. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr. Physiol. 4, 1339–1368 (2014).
pubmed: 25428846
pmcid: 4858318
doi: 10.1002/cphy.c130055
Modarresi, F. et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30, 453–459 (2012).
pubmed: 22446693
pmcid: 4144683
doi: 10.1038/nbt.2158
Hing, B. et al. A polymorphism associated with depressive disorders differentially regulates brain derived neurotrophic factor promoter IV activity. Biol. Psychiatry 71, 618–626 (2012).
pubmed: 22265241
pmcid: 3712170
doi: 10.1016/j.biopsych.2011.11.030
Maisonpierre, P. C. et al. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 5, 501–509 (1990).
pubmed: 1688327
doi: 10.1016/0896-6273(90)90089-X
Di Carlo, P., Punzi, G. & Ursini, G. Brain-derived neurotrophic factor and schizophrenia. Psychiatr. Genet. 29, 200–210 (2019).
pubmed: 31465000
pmcid: 7386257
doi: 10.1097/YPG.0000000000000237
Liu, S. Neurotrophic factors in enteric physiology and pathophysiology. Neurogastroenterol. Motil. 30, e13446 (2018).
pubmed: 30259610
pmcid: 6166659
doi: 10.1111/nmo.13446
Grider, J. R., Piland, B. E., Gulick, M. A. & Qiao, L. Y. Brain-derived neurotrophic factor augments peristalsis by augmenting 5-HT and calcitonin gene-related peptide release. Gastroenterology 130, 771–780 (2006).
pubmed: 16530518
doi: 10.1053/j.gastro.2005.12.026
Chai, N.-L. et al. Effects of neurotrophins on gastrointestinal myoelectric activities of rats. World J. Gastroenterol. 9, 1874–1877 (2003).
pubmed: 12918143
pmcid: 4611566
doi: 10.3748/wjg.v9.i8.1874
Chen, F. et al. Brain-derived neurotrophic factor accelerates gut motility in slow-transit constipation. Acta Physiol. 212, 226–238 (2014).
doi: 10.1111/apha.12374
Coulie, B. et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119, 41–50 (2000).
pubmed: 10889153
doi: 10.1053/gast.2000.8553
Taché, Y., Garrick, T. & Raybould, H. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology 98, 517–528 (1990).
pubmed: 2104814
doi: 10.1016/0016-5085(90)90849-V
Taché, Y., Kolve, E., Maeda-Hagiwara, M. & Kauffman, G. L. Central nervous system action of calcitonin to alter experimental gastric ulcers in rats. Gastroenterology 94, 145–150 (1988).
pubmed: 3335286
doi: 10.1016/0016-5085(88)90622-1
Fukudo, S., Nomura, T. & Hongo, M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42, 845–849 (1998).
pubmed: 9691924
pmcid: 1727153
doi: 10.1136/gut.42.6.845
Stengel, A. & Taché, Y. Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight. Annu. Rev. Physiol. 71, 219–239 (2009).
pubmed: 18928406
pmcid: 2714186
doi: 10.1146/annurev.physiol.010908.163221
Kaji, I. et al. Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon. Neurogastroenterol. Motil. 30, 13157 (2018).
doi: 10.1111/nmo.13157
Nøhr, M. K. et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154, 3552–3564 (2013).
pubmed: 23885020
doi: 10.1210/en.2013-1142
Soret, R. et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 138, 1772–1782 (2010).
pubmed: 20152836
doi: 10.1053/j.gastro.2010.01.053
Sinha, T. et al. Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes 10, 358–366 (2019).
pubmed: 30373468
doi: 10.1080/19490976.2018.1528822
Shastri, P., McCarville, J., Kalmokoff, M., Brooks, S. P. J. & Green-Johnson, J. M. Sex differences in gut fermentation and immune parameters in rats fed an oligofructose-supplemented diet. Biol. Sex. Differ. 6, 13 (2015).
pubmed: 26251695
pmcid: 4527341
doi: 10.1186/s13293-015-0031-0
Pittayanon, R. et al. Gut microbiota in patients with irritable bowel syndrome–a systematic review. Gastroenterology 157, 97–108 (2019).
pubmed: 30940523
doi: 10.1053/j.gastro.2019.03.049
Agnello, M. et al. Gut microbiome composition and risk factors in a large cross-sectional IBS cohort. BMJ Open Gastroenterol. 7, e000345 (2020).
pubmed: 32518661
pmcid: 7254124
doi: 10.1136/bmjgast-2019-000345
Vich Vila, A. et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci. Transl Med. 10, eaap8914 (2018).
pubmed: 30567928
doi: 10.1126/scitranslmed.aap8914
Botschuijver, S. et al. Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats. Gastroenterology 153, 1026–1039 (2017).
pubmed: 28624575
doi: 10.1053/j.gastro.2017.06.004
Mihindukulasuriya, K. A. et al. Multi-omics analyses show disease, diet, and transcriptome interactions with the virome. Gastroenterology 161, 1194–1207.e8 (2021).
pubmed: 34245762
doi: 10.1053/j.gastro.2021.06.077
Hadizadeh, F. et al. Stool frequency is associated with gut microbiota composition. Gut 66, 559–560 (2017).
pubmed: 27196592
doi: 10.1136/gutjnl-2016-311935
Tigchelaar, E. F. et al. Gut microbiota composition associated with stool consistency. Gut 65, 540–542 (2016).
pubmed: 26276682
doi: 10.1136/gutjnl-2015-310328
Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).
pubmed: 27126040
pmcid: 5240844
doi: 10.1126/science.aad3369
Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51, 600–605 (2019).
pubmed: 30778224
pmcid: 6441384
doi: 10.1038/s41588-019-0350-x
Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).
pubmed: 29489753
doi: 10.1038/nature25973
Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022).
pubmed: 35418674
doi: 10.1038/s41586-022-04567-7
Sanna, S., Kurilshikov, A., van der Graaf, A., Fu, J. & Zhernakova, A. Challenges and future directions for studying effects of host genetics on the gut microbiome. Nat. Genet. 54, 100–106 (2022).
pubmed: 35115688
doi: 10.1038/s41588-021-00983-z
Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156–165 (2021).
pubmed: 33462485
pmcid: 8515199
doi: 10.1038/s41588-020-00763-1
Hughes, D. A. et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat. Microbiol. 5, 1079–1087 (2020).
pubmed: 32572223
pmcid: 7610462
doi: 10.1038/s41564-020-0743-8
Rühlemann, M. C. et al. Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat. Genet. 53, 147–155 (2021).
pubmed: 33462482
doi: 10.1038/s41588-020-00747-1
Lopera-Maya, E. A. et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat. Genet. 54, 143–151 (2022).
pubmed: 35115690
doi: 10.1038/s41588-021-00992-y
Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 54, 134–142 (2022).
pubmed: 35115689
doi: 10.1038/s41588-021-00991-z
Goodrich, J. K. et al. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe 19, 731–743 (2016).
pubmed: 27173935
pmcid: 4915943
doi: 10.1016/j.chom.2016.04.017
Turpin, W. et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat. Genet. 48, 1413–1417 (2016).
pubmed: 27694960
doi: 10.1038/ng.3693
Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in complex traits. Nat. Genet. 51, 1339–1348 (2019).
pubmed: 31427789
doi: 10.1038/s41588-019-0481-0
Olds, L. C. & Sibley, E. Lactase persistence DNA variant enhances lactase promoter activity in vitro: functional role as a cis regulatory element. Hum. Mol. Genet. 12, 2333–2340 (2003).
pubmed: 12915462
doi: 10.1093/hmg/ddg244
Morales, E. et al. The European lactase persistence genotype determines the lactase persistence state and correlates with gastrointestinal symptoms in the Hispanic and Amerindian Chilean population: a case–control and population-based study. BMJ Open 1, e000125 (2011).
pubmed: 22021768
pmcid: 3191413
doi: 10.1136/bmjopen-2011-000125
Brandao Gois, M. F. et al. Role of the gut microbiome in mediating lactose intolerance symptoms. Gut 71, 215–217 (2022).
pubmed: 34086598
doi: 10.1136/gutjnl-2020-323911
Poole, A. C. et al. Human salivary amylase gene copy number impacts oral and gut microbiomes. Cell Host Microbe 25, 553–564.e7 (2019).
pubmed: 30974084
doi: 10.1016/j.chom.2019.03.001
Zhou, W. et al. Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases. Preprint at medRxiv https://doi.org/10.1101/2021.11.19.21266436 (2021).
doi: 10.1101/2021.11.19.21266436
pubmed: 34931200
pmcid: 8687471
Camilleri, M. & Chedid, V. Actionable biomarkers: the key to resolving disorders of gastrointestinal function. Gut 69, 1730–1737 (2020).
pubmed: 32269066
doi: 10.1136/gutjnl-2019-320325
Scholtens, S. et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int. J. Epidemiol. 44, 1172–1180 (2015).
pubmed: 25502107
doi: 10.1093/ije/dyu229
Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat. Med. 27, 1876–1884 (2021).
doi: 10.1038/s41591-021-01549-6
Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177, 26–31 (2019).
pubmed: 30901543
pmcid: 7380073
doi: 10.1016/j.cell.2019.02.048
DeBoever, C. et al. Assessing digital phenotyping to enhance genetic studies of human diseases. Am. J. Hum. Genet. 106, 611–622 (2020).
pubmed: 32275883
pmcid: 7212271
doi: 10.1016/j.ajhg.2020.03.007
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
doi: 10.1067/mcp.2001.113989
Kawahara, H., Minami, R. & Yokota, N. BAG6/BAT3: emerging roles in quality control for nascent polypeptides. J. Biochem. 153, 147–160 (2013).
pubmed: 23275523
doi: 10.1093/jb/mvs149
Binici, J. & Koch, J. BAG-6, a jack of all trades in health and disease. Cell. Mol. Life Sci. 71, 1829–1837 (2014).
pubmed: 24305946
doi: 10.1007/s00018-013-1522-y
Cheishvili, D. et al. IKAP/Elp1 involvement in cytoskeleton regulation and implication for familial dysautonomia. Hum. Mol. Genet. 20, 1585–1594 (2011).
pubmed: 21273291
doi: 10.1093/hmg/ddr036
Jackson, M. Z., Gruner, K. A., Qin, C. & Tourtellotte, W. G. A neuron autonomous role for the familial dysautonomia gene ELP1 in sympathetic and sensory target tissue innervation. Development 141, 2452–2461 (2014).
pubmed: 24917501
pmcid: 4050699
doi: 10.1242/dev.107797
Malumbres, M. et al. Cyclin-dependent kinases: a family portrait. Nat. Cell Biol. 11, 1275–1276 (2009).
pubmed: 19884882
pmcid: 2914104
doi: 10.1038/ncb1109-1275
Cole, A. R. PCTK proteins: the forgotten brain kinases? Neurosignals 17, 288–297 (2009).
pubmed: 19816065
doi: 10.1159/000231895
Vieira, N., Rito, T., Correia-Neves, M. & Sousa, N. Sorting out sorting nexins functions in the nervous system in health and disease. Mol. Neurobiol. 58, 4070–4106 (2021).
pubmed: 33931804
pmcid: 8280035
doi: 10.1007/s12035-021-02388-9
Jin, Q. et al. Novel function of FAXDC2 in megakaryopoiesis. Blood Cancer J. 6, e478 (2016).
pubmed: 27689744
pmcid: 5056977
doi: 10.1038/bcj.2016.87
Rooman, I. et al. Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. Am. J. Pathol. 169, 1206–1214 (2006).
pubmed: 17003479
pmcid: 1698841
doi: 10.2353/ajpath.2006.050926
Kadur Lakshminarasimha Murthy, P. et al. Radical and lunatic fringes modulate notch ligands to support mammalian intestinal homeostasis. eLife 7, e35710 (2018).
pubmed: 29629872
pmcid: 5896954
doi: 10.7554/eLife.35710
Katoh, M. & Katoh, M. Notch signaling in gastrointestinal tract (review). Int. J. Oncol. 30, 247–251 (2007).
pubmed: 17143535
Ratanasirintrawoot, S. & Israsena, N. Stem cells in the intestine: possible roles in pathogenesis of irritable bowel syndrome. J. Neurogastroenterol. Motil. 22, 367–382 (2016).
pubmed: 27184041
pmcid: 4930294
doi: 10.5056/jnm16023
W, C. et al. SCF-FBXO24 regulates cell proliferation by mediating ubiquitination and degradation of PRMT6. Biochem. Biophys. Res. Commun. 530, 75–81 (2020).
doi: 10.1016/j.bbrc.2020.06.007
Moore, S. W. & Johnson, G. Acetylcholinesterase in Hirschsprung’s disease. Pediatr. Surg. Int. 21, 255–263 (2005).
pubmed: 15759143
doi: 10.1007/s00383-005-1383-z
Soreq, H. & Seidman, S. Acetylcholinesterase–new roles for an old actor. Nat. Rev. Neurosci. 2, 294–302 (2001).
pubmed: 11283752
doi: 10.1038/35067589
Demir, I. E., Schäfer, K.-H., Tieftrunk, E., Friess, H. & Ceyhan, G. O. Neural plasticity in the gastrointestinal tract: chronic inflammation, neurotrophic signals, and hypersensitivity. Acta Neuropathol. 125, 491–509 (2013).
pubmed: 23417735
doi: 10.1007/s00401-013-1099-4
Kano, M. et al. Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. Sci. Rep. 7, 12425 (2017).
pubmed: 28963545
pmcid: 5622133
doi: 10.1038/s41598-017-09635-x
Sagami, Y. et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53, 958–964 (2004).
pubmed: 15194643
pmcid: 1774093
doi: 10.1136/gut.2003.018911
Taché, Y. & Million, M. Role of corticotropin-releasing factor signaling in stress-related alterations of colonic motility and hyperalgesia. J. Neurogastroenterol. Motil. 21, 8–24 (2015).
pubmed: 25611064
pmcid: 4288101
doi: 10.5056/jnm14162
Samuel, B. S. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105, 16767–16772 (2008).
pubmed: 18931303
pmcid: 2569967
doi: 10.1073/pnas.0808567105
Tazoe, H. et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed. Res. 30, 149–156 (2009).
pubmed: 19574715
doi: 10.2220/biomedres.30.149
Gee, H. Y., Tang, B. L., Kim, K. H. & Lee, M. G. Syntaxin 16 binds to cystic fibrosis transmembrane conductance regulator and regulates its membrane trafficking in epithelial cells. J. Biol. Chem. 285, 35519–35527 (2010).
pubmed: 20826815
pmcid: 2975176
doi: 10.1074/jbc.M110.162438
Tang, B. L. Syntaxin 16’s newly deciphered roles in autophagy. Cells 8, E1655 (2019).
pubmed: 31861136
doi: 10.3390/cells8121655
Longstreth, G. F. et al. Functional bowel disorders. Gastroenterology 130, 1480–1491 (2006).
pubmed: 16678561
doi: 10.1053/j.gastro.2005.11.061